ストックスクリーナーアプリを入手
23.52
0.42%
-0.10
プレマーケット:
23.11
-0.41
-1.74%
Capricor Therapeutics Inc (CAPR) 最新ニュース
FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’ - MSN
Highs Report: Whats the profit margin of Capricor Therapeutics IncBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
CAPR stock slides after FDA requests more data for genetic disorder therapy — what does retail think? - MSN
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February - TradingView — Track All Markets
Does FDA’s HOPE-3 Data Request Clarify Deramiocel’s Regulatory Path For Capricor Therapeutics (CAPR)? - Sahm
Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance
Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance
Capricor Updates Deramiocel BLA Status After FDA Review of HOPE-3 Data - filmogaz.com
Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance
Capricor (CAPR) Plans February FDA Data Submission After 2% Stock Drop - Intellectia AI
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? - Stocktwits
FDA Requests Capricor To Submit HOPE-3 Clinical Study Report For Deramiocel BLA Review - RTTNews
Capricor Therapeutics Provides Regulatory Updates Regarding Its Biologics License Application for Deramiocel - marketscreener.com
Capricor Therapeutics (CAPR) Moves Forward with Regulatory Update on Cell Therapy - GuruFocus
Capricor Therapeutics Inc. Provides Regulatory Update on Deramiocel BLA Submission Following FDA Request for HOPE-3 Clinical Study Report - Quiver Quantitative
FDA asks for full HOPE-3 data on DMD cell therapy, no new trials - Stock Titan
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageHere's Why - MarketBeat
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com UK
Cantor Fitzgerald reiterates Overweight rating on Capricor stock By Investing.com - Investing.com UK
A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Phase 3 Success And Nippon Shinyaku Deals - Sahm
EV Market: Whats the profit margin of Capricor Therapeutics Inc2025 Major Catalysts & Smart Swing Trading Techniques - baoquankhu1.vn
Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen - MarketBeat
Why Capricor Therapeutics Inc. stock attracts high net worth investorsStock Surge & Risk Controlled Daily Plans - Улправда
Capricor Therapeutics: A High Risk/High Reward Name - Seeking Alpha
Why Capricor Therapeutics (CAPR) Is Down 15.8% After Phase 3 Win And $1.5 Billion Deal - simplywall.st
Here's Why This Biotechnology Skyrocketed by 439% in December - Yahoo Finance
How interest rate cuts could boost Capricor Therapeutics Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - ulpravda.ru
Investment Recap: How interest rate cuts could boost Capricor Therapeutics Inc. stockJuly 2025 Reactions & Weekly Top Stock Performers List - ulpravda.ru
Can Capricor Therapeutics Inc. stock weather global recession2025 Geopolitical Influence & Technical Pattern Recognition Alerts - ulpravda.ru
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - FinancialContent
(CAPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8%What's Next? - MarketBeat
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat
‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% - MSN
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5%Here's What Happened - MarketBeat
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Analyst Downgrade: How interest rate cuts could boost Capricor Therapeutics Inc stockWeekly Stock Analysis & Daily Profit Focused Stock Screening - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Trend Review: Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Buyback Activity & Safe Investment Capital Preservation Plans - moha.gov.vn
HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4% - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
Capricor Therapeutics prices $150M stock offering - MSN
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
With Capricor Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Top Medical Stocks To ResearchDecember 3rd - MarketBeat
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal - Sahm
Capricor Therapeutics launches proposed public offering of common stock - MSN
Earnings Risk: Is ARK Autonomous Technology & Robotics stock cheap by valuation metricsMarket Trend Summary & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
How Capricor Therapeutics Inc. (4LN2) stock trades pre earningsQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Does Capricor Therapeutics Inc. stock trade at a discount to peers2025 Analyst Calls & Advanced Technical Signal Analysis - ulpravda.ru
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.8%What's Next? - MarketBeat
Capricor Therapeutics (STU:4LN2) EV-to-OCF : -21.03 (As of Dec. 19, 2025) - GuruFocus
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):